- ISIN
- US34960Q2084
- CUSIP
- 34960Q208
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 14, 2017
Highlights
- Market Cap
- $148.63M
- Enterprise Value
- $138.59M
- EPS (TTM)
- -$0.20
- Total Revenue (TTM)
- $63.25M
- Gross Profit (TTM)
- $31.70M
- EBITDA (TTM)
- -$21.61M
- Year Range
- $6.27 - $21.43
- ROA (TTM)
- -17.05%
- ROE (TTM)
- -63.42%
- Avg. Volume (1M)
- 13K
- Avg. Volume Value (1M)
- $244.20K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
FBIOP Performance Chart
Fortress Biotech, Inc. (FBIOP) is up 99.0% since the beginning of the year. At $19 per share, FBIOP is trading 11.9% below its 52-week high of $21. Investors who bought $1,000 worth of FBIOP shares 5 years ago would now be looking at an investment worth $1,046.
Loading charts...
Compare this symbol against anything
Returns By Period
Fortress Biotech, Inc. (FBIOP) has returned 98.95% so far this year and 172.63% over the past 12 months.
Fortress Biotech, Inc.
- 1D
- 0.43%
- 1M
- -7.50%
- 6M
- 54.75%
- YTD
- 98.95%
- 1Y
- 172.63%
- 3Y*
- 8.80%
- 5Y*
- 0.90%
- 10Y*
- —
- ALL TIME*
- 6.47%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
FBIOP Monthly Returns History
Based on dividend-adjusted daily data since Nov 14, 2017, FBIOP's average daily return is +0.08%, while the average monthly return is +1.33%. At this rate, an investment would double in approximately 4.4 years.
Historically, 60% of months were positive and 40% were negative. The best month was Dec 2025 with a return of +37.5%, while the worst month was Jul 2024 at -46.5%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, FBIOP closed higher 50% of trading days. The best single day was Aug 21, 2023 with a return of +37.2%, while the worst single day was Jul 8, 2024 at -54.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 28.56% | 18.03% | -3.40% | 3.45% | 35.30% | 3.24% | -6.07% | 98.95% | |||||
| 2025 | -3.31% | -9.49% | 3.26% | 11.48% | 17.91% | -2.53% | -10.78% | 19.17% | 12.37% | -23.91% | -1.43% | 37.54% | 42.71% |
| 2024 | 14.10% | 16.47% | 9.52% | -10.01% | 8.75% | 1.35% | -46.54% | -22.60% | -17.16% | 1.83% | 6.40% | 12.62% | -39.63% |
| 2023 | 12.99% | -0.36% | -4.58% | 1.19% | -11.95% | 10.25% | -1.65% | -34.61% | 8.44% | -17.75% | 27.77% | 1.00% | -21.89% |
| 2022 | 0.63% | -4.27% | -1.50% | -6.23% | -13.98% | -2.91% | 5.75% | 6.48% | -5.90% | 3.91% | 3.01% | -9.55% | -23.78% |
| 2021 | 8.31% | 7.42% | 8.39% | 7.14% | 2.75% | 1.34% | 1.80% | -2.68% | 3.17% | 0.86% | -0.80% | 2.02% | 46.78% |
Benchmark Metrics
Fortress Biotech, Inc. has an annualized alpha of 16.32%, beta of 0.41, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 14, 2017.
- This stock participated in 52.79% of S&P 500 Index downside but only 43.03% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.41 may look defensive, but with R2 of 0.02 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 16.32%
- Beta
- 0.41
- R²
- 0.02
- Upside Capture
- 43.03%
- Downside Capture
- 52.79%
Return for Risk
Risk / Return Rank
FBIOP ranks 97 for risk / return — above 97% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Fortress Biotech, Inc. (FBIOP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FBIOP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.54 | ||
| Sortino ratioReturn per unit of downside risk | +2.16 | ||
| Omega ratioGain probability vs. loss probability | 1.60 | 1.25 | +0.35 |
| Calmar ratioReturn relative to maximum drawdown | 5.75 | 2.00 | +3.74 |
| Martin ratioReturn relative to average drawdown | 13.81 | 8.49 | +5.32 |
Dividends
Dividend History
Fortress Biotech, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $1.17 | $2.34 | $2.34 | $2.34 | $2.34 | $2.34 | $2.34 | $0.30 |
Dividend yield | 0.00% | 0.00% | 17.62% | 19.75% | 13.28% | 9.06% | 12.09% | 11.44% | 16.29% | 1.32% |
Monthly Dividends
The table displays the monthly dividend distributions for Fortress Biotech, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.17 |
| 2023 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $2.34 |
| 2022 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $2.34 |
| 2021 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $0.20 | $2.34 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Fortress Biotech, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Fortress Biotech, Inc. was 73.54%, occurring on Oct 15, 2024. Recovery took 403 trading sessions.
The current Fortress Biotech, Inc. drawdown is 10.44%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-73.54%Oct 2024 | 2y 8mo | 1y 7mo | 4y 4moJan 2022 - May 2026 | — |
-39.42%Mar 2020 | 1mo 11d | 8mo 6d | 9mo 17dFeb 2020 - Nov 2020 | COVID crash2020 |
-36.25%Dec 2018 | 1y 1mo | 5mo 4d | 1y 6moNov 2017 - May 2019 | Rate-hike selloffLate 2018 |
-11.96%Jul 2026 | 1mo 5d | — | 1mo 29dJun 2026 - now | — |
-9.47%Mar 2021 | 17d | 12d | 29dFeb 2021 - Mar 2021 | — |
Drawdown Indicators
| FBIOP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -73.54% | -56.78% | -16.76% |
Max Drawdown (1Y)Largest decline over 1 year | -30.61% | -9.10% | -21.51% |
Max Drawdown (3Y)Largest decline over 3 years | -70.75% | -18.90% | -51.85% |
Max Drawdown (5Y)Largest decline over 5 years | -73.54% | -25.43% | -48.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -10.44% | -1.58% | -8.86% |
Average DrawdownAverage peak-to-trough decline | -22.03% | -10.70% | -11.33% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.72% | 2.14% | +10.58% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Fortress Biotech, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Fortress Biotech, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for FBIOP relative to other companies in the Biotechnology industry. Currently, FBIOP has a P/S ratio of 46.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for FBIOP in comparison with other companies in the Biotechnology industry. Currently, FBIOP has a P/B value of 105.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with FBIOP
Add Fortress Biotech, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with FBIOP